

# Gian M Baldin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9395075/gian-m-baldin-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

572  
citations

13  
h-index

22  
g-index

57  
ext. papers

732  
ext. citations

4.3  
avg, IF

3.38  
L-index

#	Paper	IF	Citations
53	Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27418	1.8	0
52	Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27418	1.8	
51	Real-life findings on the impact of the COVID-19 pandemic on HIV care.. <i>Antiviral Therapy</i> , <b>2021</b> , 26, 84-86.6		
50	Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 1317-1332	4.1	1
49	Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 333-334	1.6	
48	Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
47	Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 429-432	1.6	5
46	Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 486-488	1.6	1
45	Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. <i>HIV Medicine</i> , <b>2021</b> , 22, 843-853 <sup>2.7</sup>		3
44	Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 4-10	1.6	2
43	Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital. <i>AIDS Research and Human Retroviruses</i> , <b>2021</b> , 37, 350-356	1.6	
42	Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. <i>HIV Medicine</i> , <b>2021</b> , 22, 22-27	2.7	2
41	Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 88, 234-237	3.1	2
40	Shall We Dance? Extending TANGO <sup>2</sup> Results to Clinical Practice. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e200-e201	11.6	4
39	Dolutegravir plus lamivudine for the treatment of HIV-1 infection. <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 279-292	5.5	2
38	HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 256-257	1.6	2
37	No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir. <i>Aids</i> , <b>2020</b> , 34, 956-957	3.5	7

36	Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 4-5	1.6	7
35	How much raltegravir do you take? The answer may not be so obvious: an accidental finding from clinical practice. <i>HIV Medicine</i> , <b>2020</b> , 21, e1-e2	2.7	
34	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , <b>2019</b> , 1-7	1.7	5
33	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 728-734	14.3	21
32	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25227	5.4	24
31	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 59	4	13
30	Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. <i>HIV Medicine</i> , <b>2019</b> , 20, 624-627	2.7	2
29	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts $\geq 5 \log_{10}$ copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 2732-2741	5.1	5
28	Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 54, 487-490	14.3	6
27	Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 2470-2472	5.1	
26	Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016. <i>Epidemiology and Infection</i> , <b>2019</b> , 147, e89	4.3	10
25	Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1461-1463	5.1	16
24	Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , <b>2019</b> , 169, 104552	10.8	13
23	Case Report: Multifocal Tubercular Osteomyelitis of the Spine and Bilateral Dactylitis. <i>American Journal of Tropical Medicine and Hygiene</i> , <b>2019</b> , 101, 494-497	3.2	0
22	Cohort profile: The Observational cohort for the study of Dolutegravir in Antiretroviral Combination Regimens (ODOACRE). <i>BMJ Open</i> , <b>2019</b> , 9, e029960	3	7
21	Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study. <i>HIV Medicine</i> , <b>2019</b> , 20, 164-168	2.7	18
20	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , <b>2019</b> , 20, 99-109	2.7	11
19	A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 63-67	1.6	23

18	Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study. <i>Infezioni in Medicina</i> , <b>2019</b> , 27, 410-414	3.6	1
17	An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. <i>HIV Medicine</i> , <b>2018</b> , 19, 369-375	2.7	7
16	Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. <i>HIV Medicine</i> , <b>2018</b> , 19, 452	2.7	23
15	HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. <i>Journal of Clinical Virology</i> , <b>2018</b> , 103, 57-62	14.5	2
14	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. <i>HIV Clinical Trials</i> , <b>2018</b> , 19, 242-248		12
13	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 3460-3470	5.1	7
12	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1949-1954	5.1	14
11	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , <b>2018</b> , 19, 475	2.7	10
10	Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. <i>Infezioni in Medicina</i> , <b>2018</b> , 26, 336-340	3.6	11
9	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , <b>2017</b> , 23, 267.e1-267.e4	9.5	7
8	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186549	3.7	18
7	A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks observational data. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 658	4	37
6	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , <b>2017</b> , 31, 457-459	3.5	32
5	Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 257-262	1.6	15
4	Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2359-61	5.1	21
3	Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 719-24	9.5	5
2	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 1601-10	14.5	125
1	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140877	3.7	7

